BICO Group (OTCPK:CLLK.F) - Stock Price, News & Analysis

CLLK.F Stock Overview

BICO Group AB (publ) ist als Biokonvergenzunternehmen in Nordamerika, Europa, Asien und international tätig.

CLLK.F fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Prognostiziertes Gewinnwachstum 108.86% pro Jahr

Risk Analysis

Aktien sind hochgradig illiquide

BICO Group AB (publ) Competitors

Inotiv

NasdaqCM:NOTV

US$244.0m

Akoya Biosciences

NasdaqGS:AKYA

US$212.8m

ChromaDex

NasdaqCM:CDXC

US$298.1m

Standard BioTools

NasdaqGM:SLGC

US$396.2m

Price History & Performance

Summary of all time highs, changes and price drops for BICO Group
Historical stock prices
Current Share Price	kr4.15
52 Week High	kr6.90
52 Week Low	kr2.28
Beta	2.34
1 Month Change	12.16%
3 Month Change	-32.96%
1 Year Change	-18.63%
3 Year Change	-90.98%
5 Year Change	-87.25%
Change since IPO	-70.73%

Recent updates

Shareholder Returns

	CLLK.F	US Life Sciences	US Market
7D	4.0%	-3.4%	-2.1%
1Y	-18.6%	-0.4%	24.7%

Rendite im Vergleich zur Industrie: CLLK.F unter dem Niveau der Branche US Life Sciences , die im vergangenen Jahr eine Rendite von -0.5% erzielte.

Rendite vs. Markt: CLLK.F hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 22.3 erzielte.

Price Volatility

Is CLLK.F's price volatile compared to industry and market?
CLLK.F volatility
CLLK.F Average Weekly Movement	n/a
Life Sciences Industry Average Movement	7.2%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.0%

Stabiler Aktienkurs: CLLK.FDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: Unzureichende Daten, um die Volatilitätsveränderung von CLLK.F im vergangenen Jahr zu bestimmen.

About the Company

Founded	Employees	CEO	Website
2016	880	Maria Forss	https://www.bico.com

BICO Group AB (publ) ist als Biokonvergenzunternehmen in Nordamerika, Europa, Asien und international tätig. Das Unternehmen ist in drei Segmenten tätig: Bioprinting, Biosciences und Bioautomation. Das Segment Bioprinting bietet Produkte, Lösungen und Dienstleistungen an, die die Verbreitung von 3D-Zellkulturen und 3D-Druck ermöglichen.

BICO Group AB (publ) Fundamentals Summary

How do BICO Group's earnings and revenue compare to its market cap?
CLLK.F fundamental statistics
Market cap	US$301.61m
Earnings (TTM)	-US$159.38m
Revenue (TTM)	US$225.87m

1.3x

P/S Ratio

-1.9x

P/E Ratio

Is CLLK.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CLLK.F income statement (TTM)
Revenue	kr2.40b
Cost of Revenue	kr673.10m
Gross Profit	kr1.73b
Other Expenses	kr3.43b
Earnings	-kr1.70b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 07, 2024

Earnings per share (EPS)	-24.04
Gross Margin	72.01%
Net Profit Margin	-70.56%
Debt/Equity Ratio	29.0%

How did CLLK.F perform over the long term?

See historical performance and comparison

CLLK.F Stock Overview

Rewards

Risk Analysis

BICO Group AB (publ) Competitors

NasdaqCM:NOTV

US$244.0m

NasdaqGS:AKYA

US$212.8m

NasdaqCM:CDXC

US$298.1m

NasdaqGM:SLGC

US$396.2m

Price History & Performance

Recent News & Updates

BICO Group AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025

BICO Group AB (publ) to Report Q3, 2024 Results on Nov 13, 2024

BICO Group AB (publ) Appoints Catharina Nordlund as Global Head of HR

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Mar 15, 2024

BICO Group AB (publ) Announces Chief Executive Officer Changes

Beos Light Industrial Germany 1 Fund, a fund managed by BEOS AG agreed to acquire property on Wagner-Régeny-Straße 15 from BICO Group AB (publ) (OM:BICO) for €21 million.

Recent updates

BICO Group AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025

BICO Group AB (publ) to Report Q3, 2024 Results on Nov 13, 2024

BICO Group AB (publ) Appoints Catharina Nordlund as Global Head of HR

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Mar 15, 2024

BICO Group AB (publ) Announces Chief Executive Officer Changes

Beos Light Industrial Germany 1 Fund, a fund managed by BEOS AG agreed to acquire property on Wagner-Régeny-Straße 15 from BICO Group AB (publ) (OM:BICO) for €21 million.

BICO Group AB (publ) Elects Gerry Mackay to Its Board of Directors

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

BICO Group AB Appoints Marius Balger as Chief Operating Officer, Effective March 1, 2023

BICO Group AB Announces the Appointment of Jacob Thordenberg as Group CFO

BICO Group AB (publ) to Report Q1, 2023 Results on May 04, 2023

BICO Group AB (publ) to Report Q2, 2023 Results on Jul 20, 2023

BICO Group Announces Appointment of Nomination Committee 2023

BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2023

BICO Group Adds Åsa Hillsten as SVP and Head of IR

BICO Group AB (publ) (OM : BICO) acquired Allegro 3D for $11 million.

BICO (publ) Appoints Mikael Engblom as Interim CFO

BICO Group AB (Publ) Announces Board Appointments

BICO Reaches Beneficial and Sustainable Solution with Organovo

DISPENDIX, A BICO Company, Announces That the I.DOT HT Non-contact Dispenser and the L.DROP Liquid Handler will be introduced at SLAS 2022

BICO Group AB Announces Statement Regarding Counterclaims in Patent Lawsuit by Organovo Against Cellink

BICO Group AB (publ) (OM:BICO) agreed to acquire Biosero Llc.

BICO Group AB (publ) (OM:BICO) acquired all outstanding shares in Advanced BioMatrix, Inc. for $18 million.

CELLINK Receives Patent for Robotic Systems for Personalized and Automated Aesthetic Medical Procedures

Cellink AB (publ) (OM:CLNK B) completed the acquisition of Discover Echo Inc.

Cellink AB (publ) (OM:CLNK B) completed the acquisition of Nanoscribe GmbH for approximately €37 million.

Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Nanoscribe GmbH for €34 million.

Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire MatTek Corporation for $68 million.

Cellink AB (publ) (OM:CLNK B) completed the acquisition of Ginolis Ltd from Verso Fund II of Verso Capital Oy, Finnvera plc and Innovestor Ventures for €65.7 million.

Cellink AB (publ) to Report Fiscal Year 2021 Results on Mar 16, 2022

Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Ginolis Ltd for €70 million.

Cellink AB (publ) Announces Distribution Agreement Including New Products for Single-Cell RNA Sequencing and NGS Library Preparation

Cellink Announces Third Year Extension of Collaboration with A Global Biopharmaceutical Company for Drug Discovery

Cellink and Phasefocus Announces a Partnership to Bring Livecyte High Content Live Cell Imager to a Wider Audience

Cellink AB (publ) Elects Aristotelis Nastos as Member of the Board of Directors

CELLINK and Atelerix Team Up to Enable the Shipping At Room Temperature of Fragile 3D Bioprinted Constructs by the World's Bioprinting Community

CELLINK to Help Develop 3D Bioprinted Personalised Scaffolds for Tissue Regeneration of Ankle Joint S as Part of the Triankle Project

Cellink AB (publ) to Report Second Half, 2020 Results on Oct 22, 2020

Cellink AB (Publ) Announces Leaving Board of Directors for an Operational Role as Business Area Manager for the Bioprinting Business Unit

Cellink AB (publ) (OM:CLNK B) completed the acquisition of SCIENION AG from NRW.Bank Venture Fonds, L.P., managed by NRW.Bank, Investment Arm and other shareholders.

Cellink AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 945.99632 million.